MEC
MCID: MCP006
MIFTS: 48

Mucoepidermoid Carcinoma (MEC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

MalaCards integrated aliases for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 12 20 15 70
Salivary Gland Mucoepidermoid Carcinoma 12
Carcinoma, Mucoepidermoid 44
Carcinoma Mucoepidermoid 54
C3772 20
Mec 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4531
MeSH 44 D018277
NCIt 50 C3772
SNOMED-CT 67 4079000
UMLS 70 C0206694

Summaries for Mucoepidermoid Carcinoma

GARD : 20 Mucoepidermoid carcinoma is a type of cancer of the salivary glands. Salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas. Mucoepidermoid carcinoma develops when a cell randomly acquires changes ( mutations ) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump). The earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing. Treatment often begins with surgery to remove the entire tumor. In some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body.

MalaCards based summary : Mucoepidermoid Carcinoma, also known as salivary gland mucoepidermoid carcinoma, is related to lacrimal gland mucoepidermoid carcinoma and thyroid gland mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is LINC00473 (Long Intergenic Non-Protein Coding RNA 473). The drugs Bevacizumab and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, thyroid and tongue.

Disease Ontology : 12 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia : 73 Mucoepidermoid carcinoma (MEC) is the most common type of minor salivary gland malignancy in adults.... more...

Related Diseases for Mucoepidermoid Carcinoma

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 610)
# Related Disease Score Top Affiliating Genes
1 lacrimal gland mucoepidermoid carcinoma 32.9 MAML2 CRTC1
2 thyroid gland mucoepidermoid carcinoma 32.9 TG CALCA
3 breast mucoepidermoid carcinoma 32.8 MUC5AC MAML2 CRTC1
4 laryngeal mucoepidermoid carcinoma 32.7 KRT14 ERBB2 CEACAM5
5 cutaneous mucoepidermoid carcinoma 32.6 MAML2 KRT7 CRTC1 CEACAM5
6 ceruminous adenocarcinoma 32.3 KRT7 KRT14
7 bile duct mucoepidermoid carcinoma 32.2 MUC5AC MUC4 MUC1 MAML2 KRT7 CRTC1
8 lung mucoepidermoid carcinoma 32.2 MUC5AC MAML2
9 salivary gland carcinoma 31.9 TP63 SERPINA3 MAML2 KRT7 ERBB2 EGFR
10 warthin tumor 31.4 MAML2 KRT7 CRTC3 CRTC1
11 pancreatic adenosquamous carcinoma 31.1 MAML2 CRTC3 CRTC1
12 pleomorphic adenoma 31.0 TP63 S100A1 MUC1 MAML2 KRT7 KRT14
13 pleomorphic adenoma carcinoma 31.0 MAML2 ERBB2 CRTC3 CRTC1
14 adenoma 30.9 TG MUC5AC MUC1 KRT7 CHGA
15 adenosquamous carcinoma 30.9 TP63 SERPINA3 MUC4 MUC1 MAML2 KRT7
16 myoepithelial carcinoma 30.8 MUC1 KRT7 KRT14
17 in situ carcinoma 30.8 SERPINA3 MUC1 KRT14 ERBB2 EGFR
18 intrahepatic cholangiocarcinoma 30.7 MUC5AC MUC4 MUC1 KRT7 ERBB2 EGFR
19 adenoid cystic carcinoma 30.7 TP63 SERPINA3 S100A1 MUC1 KRT7 KRT14
20 oncocytoma 30.7 S100A1 MUC1 KRT7 KRT14
21 necrotizing sialometaplasia 30.7 TP63 KRT7
22 acinar cell carcinoma 30.6 SERPINA3 KRT7 CHGA
23 carcinosarcoma 30.6 S100A1 MUC1 KRT7 ERBB2 EGFR
24 papilloma 30.6 TP63 KRT7 KRT14 KRT13 ERBB2 EGFR
25 hidradenoma 30.6 MUC1 MAML2 KRT7 CRTC3 CRTC1 CEACAM5
26 polymorphous low-grade adenocarcinoma 30.6 TP63 S100A1 MUC1
27 cervical adenosquamous carcinoma 30.5 MAML2 EGFR CRTC1
28 adenocarcinoma 30.5 MUC4 MUC1 KRT7 ERBB2 EGFR CEACAM5
29 thymic carcinoma 30.5 TP63 TG MUC1 KRT7 EGFR CEACAM5
30 mammary analogue secretory carcinoma 30.5 MUC4 MUC1 EGFR
31 cholangiocarcinoma 30.5 MUC5AC MUC4 MUC1 KRT7 ERBB2 EGFR
32 papillary carcinoma 30.5 TP63 TG S100A1 MUC1 KRT7 ERBB2
33 esophageal adenosquamous carcinoma 30.5 KRT7 KRT14 ERBB2 CEACAM5
34 lymphoepithelioma-like carcinoma 30.5 MUC1 KRT7 EGFR
35 submandibular gland cancer 30.4 ERBB2 EGFR
36 clear cell hidradenoma 30.4 MAML2 KRT7 CRTC3 CRTC1 CEACAM5
37 pleomorphic carcinoma 30.4 KRT7 KRT14 EGFR
38 bronchiolo-alveolar adenocarcinoma 30.4 MUC5AC MUC4 KRT7 EGFR CEACAM5
39 nodular hidradenoma 30.4 MUC1 CEACAM5
40 mammary paget's disease 30.4 MUC1 KRT7 KRT14 ERBB2 EGFR CALCA
41 intraductal papilloma 30.4 TP63 KRT7 KRT14 ERBB2
42 sweat gland cancer 30.3 KRT7 ERBB2 CEACAM5
43 mature teratoma 30.3 KRT7 ERBB2 CEACAM5
44 squamous cell carcinoma 30.3 TP63 MUC1 KRT7 ERBB2 EGFR CEACAM5
45 appendix adenocarcinoma 30.3 KRT7 CHGA
46 lung benign neoplasm 30.3 KRT7 EGFR CHGA
47 spindle cell sarcoma 30.3 SERPINA3 MUC1 KRT7
48 syringocystadenoma papilliferum 30.2 SERPINA3 MUC1
49 papillary adenocarcinoma 30.2 MUC1 KRT7 ERBB2 CEACAM5
50 myoepithelioma 30.2 TP63 S100A1 MUC1 KRT14

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to Mucoepidermoid Carcinoma

Symptoms & Phenotypes for Mucoepidermoid Carcinoma

Drugs & Therapeutics for Mucoepidermoid Carcinoma

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
2
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
3
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
4
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
5
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
6
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
7
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
8
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
9 Protein Kinase Inhibitors Phase 1, Phase 2
10 Angiogenesis Inhibitors Phase 1, Phase 2
11 Immunoglobulins, Intravenous Phase 1, Phase 2
12 Antibodies, Monoclonal Phase 1, Phase 2
13 Immunologic Factors Phase 1, Phase 2
14
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
15 Neurotransmitter Agents Phase 1, Phase 2
16 Fluorides Phase 1, Phase 2
17 Fluorodeoxyglucose F18 Phase 1, Phase 2
18 Radiopharmaceuticals Phase 1, Phase 2
19 Arginyl-glycyl-aspartic acid Phase 1, Phase 2
20 N-Methylaspartate Phase 1, Phase 2
21 Respiratory System Agents Phase 2
22 Antidotes Phase 2
23 Expectorants Phase 2
24 N-monoacetylcystine Phase 2
25 Anti-Infective Agents Phase 2
26 Antioxidants Phase 2
27 Antiviral Agents Phase 2
28 Protective Agents Phase 2
29 Immunoglobulins Phase 1, Phase 2
30 Mitogens Phase 1, Phase 2
31 Antibodies Phase 1, Phase 2
32 Anticoagulants Phase 2
33 fucoidan Phase 2
34 Anti-Ulcer Agents Phase 2
35 Gastrointestinal Agents Phase 2
36 Antacids Phase 2
37 Anti-Inflammatory Agents Phase 2
38 Antineoplastic Agents, Immunological Phase 2
39
Arginine Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
40
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
41
Hydroxyurea Approved Phase 1 127-07-1 3657
42
Fluorouracil Approved Phase 1 51-21-8 3385
43
Lenograstim Approved, Investigational Phase 1 135968-09-1
44
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
45
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
46
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
47
Sirolimus Approved, Investigational Phase 1 53123-88-9 6436030 5284616
48
7-hydroxystaurosporine Experimental, Investigational Phase 1 112953-11-4 72271
49 topoisomerase I inhibitors Phase 1
50 Immunosuppressive Agents Phase 1

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
2 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
3 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
4 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
5 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
6 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
7 A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck Recruiting NCT04597476 Phase 2
8 Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma Terminated NCT00126607 Phase 2
9 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
10 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
11 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
12 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
13 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
14 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
15 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
16 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
17 Surgical Management of Multiple Mucoepidermoid Carcinoma and Adenocarcinoma Completed NCT03988959
18 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
19 L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study Completed NCT01155609
20 A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System Recruiting NCT01473784
21 A Phase II Study of Intensity-Modulated or Proton Radiation Therapy for Locally Advanced Sinonasal Malignancy Recruiting NCT01586767
22 Prospective Evaluation of Esophageal Pathology Treatment of Head and Neck Carcinoma Terminated NCT01164566
23 Outcomes in Transoral Robotic Microsurgery for Head and Neck Tumors Terminated NCT01254734

Search NIH Clinical Center for Mucoepidermoid Carcinoma

Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

Anatomical Context for Mucoepidermoid Carcinoma

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

40
Salivary Gland, Thyroid, Tongue, Trachea, Lymph Node, Endothelial, Thymus

Publications for Mucoepidermoid Carcinoma

Articles related to Mucoepidermoid Carcinoma:

(show top 50) (show all 2714)
# Title Authors PMID Year
1
Primary mucoepidermoid carcinoma of the skin expressing p63. 61 54
19786853 2010
2
Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. 61 54
19531414 2009
3
Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene. 61 54
19185385 2009
4
Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. 61 54
18992960 2009
5
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. 61 54
18542074 2008
6
Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy. 54 61
18202792 2008
7
Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. 61 54
17391298 2007
8
Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. 61 54
16996786 2006
9
Clinicopathologic and immunohistochemical study of intraoral mucoepidermoid carcinoma. 61 54
16564385 2006
10
Clinical prognostic factors in malignant parotid gland tumors. 61 54
16274796 2005
11
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. 61 54
16009452 2005
12
Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. 61 54
15880136 2005
13
MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. 54 61
15958852 2005
14
PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. 61 54
15308260 2004
15
MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. 61 54
15054739 2004
16
Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. 61 54
12021924 2002
17
Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. 54 61
11598171 2001
18
High tumor grade in salivary gland mucoepidermoid carcinomas and loss of expression of transforming growth factor beta receptor type II. 54 61
11405868 2001
19
Application of immunohistochemistry to the diagnosis of salivary gland tumors. 61 54
10981871 2000
20
Proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of salivary glands. 61 54
10810331 2000
21
Immunohistochemical study of basaloid squamous cell carcinoma, adenoid cystic and mucoepidermoid carcinoma in the upper aerodigestive tract. 54 61
10810423 2000
22
Fine needle aspiration biopsy of salivary gland lesions. A reappraisal of pitfalls and problems. 54 61
9684573 1998
23
A new view of the so-called adenoma malignum of the uterine cervix. 61 54
9565340 1998
24
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in human benign and malignant epithelial lesions of the parotid gland. 54 61
9192550 1997
25
[Expression of proliferating cell nuclear antigen and tumor suppressor gene P53 in mucoepidermoid carcinoma of salivary glands]. 61 54
9592256 1996
26
Radioimmunological and immunohistochemical study of carcinoembryonic antigen in pleomorphic adenoma and mucoepidermoid carcinoma of the salivary glands. 61 54
8705787 1996
27
Primary mucoepidermoid carcinoma of the thyroid gland: a report of six cases and a review of the literature of a follicular epithelial-derived tumor. 54 61
7557943 1995
28
Staging of salivary gland neoplasms: role of histopathologic and molecular factors. 54 61
7977956 1994
29
High correlation with survival of proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of the parotid gland. 61 54
7936679 1994
30
Mucoepidermoid carcinoma of the salivary glands: immunohistochemical distribution of intermediate filament proteins, involucrin and secretory proteins. 54 61
1377895 1992
31
Immunoprofile of mucoepidermoid carcinomas of minor salivary glands. 61 54
1706081 1991
32
Role of fine needle aspiration in malignant parotid tumors at a single-center experience: A retrospective cohort study. 61
33786169 2021
33
Mast Cells and Proteins Related to Myofibroblast Differentiation (PAR-2, IL-6, and TGFβ1) in Salivary Cancers: A Preliminary Study. 61
33797435 2021
34
mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells. 61
33073679 2021
35
In vitro dosimetry analyses for acrolein exposure in normal human lung epithelial cells and human lung cancer cells. 61
33385576 2021
36
Sclerosing mucoepidermoid carcinoma of the salivary glands: report of three cases with special concern to the counterpart accompanied by eosinophilia. 61
33796950 2021
37
High-grade mucoepidermoid carcinoma in the thyroid gland with poor prognosis. 61
33662196 2021
38
Primary pulmonary mucoepidermoid carcinoma: Cyto-histologic correlation and review of the literature. 61
33450549 2021
39
Salivary-Like Tumors of the Thyroid: A Comprehensive Review of Three Rare Carcinomas. 61
32562215 2021
40
Conjunctival Carcinomas Arising in the Anophthalmic Socket. 61
33705043 2021
41
Osseointegrated Implants for Orbito-Facial Prostheses: Common Complications and Solutions. 61
33741879 2021
42
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. 61
33169486 2021
43
Recent updates in salivary gland tumors of the lung. 61
33744018 2021
44
Molecular Pathology of Salivary Gland Neoplasms: Diagnostic, Prognostic, and Predictive Perspective. 61
33405400 2021
45
Taking a step down on the reconstruction ladder for head and neck reconstruction during the COVID-19 pandemic. 61
33685447 2021
46
Pericardial metastasis of parotid mucoepidermoid carcinoma diagnosed by pericardial biopsy. 61
33750609 2021
47
Development of Kikuchi-Fujimoto disease after a cervical lymph node metastasis of mucoepidermoid carcinoma: a case report. 61
32856133 2021
48
[Malignant melanoma of the mandible with mucoepidermoid carcinoma: report of a case]. 61
33677897 2021
49
Mucoepidermoid carcinoma of retromolar area: an incidental finding. 61
33766966 2021
50
Different effects of bronchoscopic interventions on children and adults with tracheobronchial mucoepidermoid carcinoma. 61
33745406 2021

Variations for Mucoepidermoid Carcinoma

Cosmic variations for Mucoepidermoid Carcinoma:

9 (show top 50) (show all 451)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97921670 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 16
2 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 16
3 COSM133255277 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.117A>C p.K39N 9:99129081-99129081 16
4 COSM97906020 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 16
5 COSM105721467 HRAS salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 16
6 COSM131674386 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 12
7 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 12
8 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 12
9 COSM110312003 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 12
10 COSM113659175 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 12
11 COSM99562983 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 12
12 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 12
13 COSM86842324 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3854C>G p.T1285S 15:43422086-43422086 12
14 COSM88223810 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 12
15 COSM93449405 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 12
16 COSM144019757 TP53 salivary gland,minor,carcinoma,NS c.742G>T p.D248Y 17:7674188-7674188 12
17 COSM106059381 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
18 COSM142685575 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.433G>C p.D145H 17:7675062-7675062 12
19 COSM105632589 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 12
20 COSM142828002 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.384G>C p.Q128H 17:7675111-7675111 12
21 COSM144319685 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.406C>T p.R136C 17:7675089-7675089 12
22 COSM111908814 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161= 17:7675129-7675129 12
23 COSM144039683 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.461A>T p.Q154L 17:7675118-7675118 12
24 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
25 COSM122563517 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.173C>A p.P58H 17:7674962-7674962 12
26 COSM144178960 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.92C>A p.P31H 17:7674962-7674962 12
27 COSM143262651 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.73G>C p.D25H 17:7675062-7675062 12
28 COSM105627143 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
29 COSM144129656 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.184G>A p.E62K 17:7674870-7674870 12
30 COSM106065020 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 12
31 COSM144706904 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.544G>A p.E182K 17:7674870-7674870 12
32 COSM143946884 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 12
33 COSM144554314 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.452C>A p.P151H 17:7674962-7674962 12
34 COSM143374203 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 12
35 COSM144013113 TP53 salivary gland,minor,carcinoma,NS c.491G>A p.R164H 17:7675088-7675088 12
36 COSM93183307 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 12
37 COSM93239617 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 12
38 COSM144109523 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.17A>T p.Q6L 17:7675118-7675118 12
39 COSM111765171 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
40 COSM112283179 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 12
41 COSM142842148 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
42 COSM88218639 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 12
43 COSM144182805 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.24G>C p.Q8H 17:7675111-7675111 12
44 COSM142858982 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 12
45 COSM145021213 TP53 salivary gland,minor,carcinoma,NS c.877-1G>A p.? 17:7670716-7670716 12
46 COSM144082461 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.6C>T p.A2= 17:7675129-7675129 12
47 COSM143166669 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.46C>T p.R16C 17:7675089-7675089 12
48 COSM144943249 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.452C>A p.P151H 17:7674962-7674962 12
49 COSM144091358 TP53 salivary gland,minor,carcinoma,NS c.298G>T p.D100Y 17:7674188-7674188 12
50 COSM142563012 TP53 salivary gland,minor,carcinoma,NS c.877-1G>A p.? 17:7670716-7670716 12

Expression for Mucoepidermoid Carcinoma

Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for Mucoepidermoid Carcinoma

GO Terms for Mucoepidermoid Carcinoma

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 TG SERPINA3 MUC5AC MUC4 MUC1 EGFR
2 extracellular region GO:0005576 9.32 TG SERPINA3 S100A1 MUC5AC MUC4 MUC1

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.46 KRT7 KRT14 KRT13 CDH3
2 O-glycan processing GO:0016266 9.13 MUC5AC MUC4 MUC1
3 negative regulation of ERBB signaling pathway GO:1901185 8.62 ERBB2 EGFR

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding protein binding GO:0008140 8.62 CRTC3 CRTC1

Sources for Mucoepidermoid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....